AlCP,
This has to stop...you are wasting everyone's timing. I am now only replying to you to help educate others who are truly interested in the Company and to offset the misinformation you are peddling through your breathtaking lack of understanding for RSH and its technology...!
1) Didn't Wheezo get FDA and CE approval as a Class I device so the device was never going down the diagnostic tool route? THIS HAS ALREADY BEEN ANSWERED IN MULTIPLE OF MY PREVIOUS POSTS. FOR THE 10TH TIME, IT WAS APPROVED AS A CLASS 1 AND NEVER TO BE USED FOR DIAGNOSIS (DON'T EVER BRING THIS UP AGAIN).
2) Wouldn't you more confident if Wheezo was tested against spirometry which is way less subjective than the stethoscope. This is evident by the disagreement between the physicians in the latest clinical trial result and subsequently the data was removed to get the better accuracy, I've never seen this practice before in clinical trial results!!!!!????? I AM COMPLETELY COMFORTABLE AND CONFIDENT WITH THE WHEEZO AS TESTED AGAINST THE STETHOSCOPE AS OPPOSED TO SPIROMETRY. YOU OBVIOUSLY HAVEN'T READ OR COMPREHENDED MY PREVIOUS POSTS WHEREBY SPIROMETRY HAS NO RELEVANCE TO ONGOING MONITORING AND MANAGEMENT FOR MY SONS ASTHMA WHEREAS A DOCTOR WITH A STETHOSCOPE DOES (HIS DOCTOR USES IT FOR HIS CHECK-UPS). STETHOSCOPE MAY BE SUBJECTIVE AND HENCE THE HUGE OPPORTUNITY FOR WHEEZO FOR ASSISTING DOCTORS GET MORE OBJECTIVE MEASUREMENTS FOR THEIR ASTHMA PATIENTS & SPIROMETRY MAY BE LESS SUBJECTIVE HOWEVER IT IS NOT OBJECTIVE LIKE WHEEZO (GIVES A % RESULTS AFTER 30 SECONDS) AND IS ONLY UTILISED IN DIAGNOSIS (AGAIN DON'T EVER BRING THIS UP AGAIN). OUTLIERS CAN & ARE REMOVED FROM DATA SETS ALL THE TIME FOR STATISCTICAL MATERIALITY SO UNLESS YOU ARE EXPERIENCED WITH EVERY CLINICAL TRIAL THAT HAS EVER BEEN CONDUCTED AND UNDERSTAND HOW THEY ARE CONDUCTED AND THE RESULTS CAPTURED, YOU WOULDN'T KNOW CATEGORICALLY WHETHER IT IS DONE OR NOT.
3) Management has told me a few months ago that the previous version of Wheezo was tested against both the stethoscope and spirometry. Hence why fixated on this as the latest clinical trial didn't. AS I HAVE SAID PREVIOUSLY, MANAGEMENT KNOW SIGNIFCANTLY MORE THAN I DO ABOUT THE TECHNOLOGY, CHRONIC RESPIRATORY DISEASE AND ARE DOING A TRULY FANTASTIC JOB AT COMMERCIALISING THE PRODUCTS AND BRINGING THEM TO MARKET TO BENEFIT ALL ASTHMATICS. (DON'T ASK THIS AGAIN, ASK MANAGEMENT).
4) Agree DTC as a screening tool will need to be treated different hence the easier path to approval then diagnostic tool which has to be used by clinician in consultation. AND THIS IS WHY RAP WILL NEVER GET FDA APPROVAL AND WILL NEVER HAVE A DIRECT TO CONSUMER PRODUCT AS COMPARED TO RSH AND ITS WHEEZO SYSTEM.
- Forums
- ASX - By Stock
- Product tests & clinical results, facts please
AlCP, This has to stop...you are wasting everyone's timing. I am...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RSH (ASX) to my watchlist
|
|||||
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $34.68M |
Open | High | Low | Value | Volume |
2.8¢ | 2.8¢ | 2.7¢ | $13.99K | 517.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 165 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 108649 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 165 | 0.027 |
7 | 297800 | 0.026 |
3 | 799992 | 0.025 |
1 | 250000 | 0.024 |
2 | 68161 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 108649 | 2 |
0.029 | 181071 | 3 |
0.030 | 630553 | 3 |
0.033 | 18333 | 1 |
0.034 | 400000 | 1 |
Last trade - 15.17pm 19/08/2024 (20 minute delay) ? |
Featured News
RSH (ASX) Chart |